![ESMO Virtual Congress 2020: The Final Overall Survival Analysis of the PROfound Study: Olaparib vs Physician's Choice of Enzalutamide or Abiraterone in Patients with mCRPC and Homologous Recombination Repair Gene Alteration ESMO Virtual Congress 2020: The Final Overall Survival Analysis of the PROfound Study: Olaparib vs Physician's Choice of Enzalutamide or Abiraterone in Patients with mCRPC and Homologous Recombination Repair Gene Alteration](https://www.urotoday.com/images/ESMO2020_Mateo_PrOfound_6.png)
ESMO Virtual Congress 2020: The Final Overall Survival Analysis of the PROfound Study: Olaparib vs Physician's Choice of Enzalutamide or Abiraterone in Patients with mCRPC and Homologous Recombination Repair Gene Alteration
![Association between CTC AR-V7 and overall survival in mCRPC. A total... | Download Scientific Diagram Association between CTC AR-V7 and overall survival in mCRPC. A total... | Download Scientific Diagram](https://www.researchgate.net/publication/332699847/figure/fig4/AS:865079977336832@1583262547509/Association-between-CTC-AR-V7-and-overall-survival-in-mCRPC-A-total-of-162-mCRPC.jpg)
Association between CTC AR-V7 and overall survival in mCRPC. A total... | Download Scientific Diagram
Overall survival. mCRPC metastatic castration-resistant protate cancer.... | Download Scientific Diagram
![Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience | Radiation Oncology | Full Text Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience | Radiation Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13014-020-01732-y/MediaObjects/13014_2020_1732_Fig2_HTML.png)
Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience | Radiation Oncology | Full Text
![In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database - European Urology Focus In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database - European Urology Focus](https://www.eu-focus.europeanurology.com/cms/attachment/2119003904/2087865617/gr1.jpg)
In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database - European Urology Focus
![Real World Patterns of PSA Response and Survival with Abiraterone and Enzalutamide in Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Clinical Oncology and Research | Science Repository | Open Access Real World Patterns of PSA Response and Survival with Abiraterone and Enzalutamide in Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Clinical Oncology and Research | Science Repository | Open Access](https://www.sciencerepository.org/articles/figures/COR-2020-7-111_2.png)
Real World Patterns of PSA Response and Survival with Abiraterone and Enzalutamide in Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Clinical Oncology and Research | Science Repository | Open Access
![Median overall survival (in months) for patients who did not receive... | Download Scientific Diagram Median overall survival (in months) for patients who did not receive... | Download Scientific Diagram](https://www.researchgate.net/publication/348664157/figure/fig3/AS:982662579777536@1611296424519/Median-overall-survival-in-months-for-patients-who-did-not-receive-any-chemotherapy.png)
Median overall survival (in months) for patients who did not receive... | Download Scientific Diagram
![Prediction of survival rate among studied mCRPC patients based on serum... | Download Scientific Diagram Prediction of survival rate among studied mCRPC patients based on serum... | Download Scientific Diagram](https://www.researchgate.net/publication/345040225/figure/fig3/AS:952564610764806@1604120509541/Prediction-of-survival-rate-among-studied-mCRPC-patients-based-on-serum-Hb-levels-prior.png)
Prediction of survival rate among studied mCRPC patients based on serum... | Download Scientific Diagram
![Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study | Journal of Nuclear Medicine Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/62/8/1050/F4.large.jpg)
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study | Journal of Nuclear Medicine
![a) Progression free and b) overall survival probability of patients... | Download Scientific Diagram a) Progression free and b) overall survival probability of patients... | Download Scientific Diagram](https://www.researchgate.net/publication/307576966/figure/fig3/AS:411970319732741@1475232786945/a-Progression-free-and-b-overall-survival-probability-of-patients-with-mCRPC-under.png)
a) Progression free and b) overall survival probability of patients... | Download Scientific Diagram
![ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone](https://www.urotoday.com/images/OS_CARD_trial.png)
ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone
![Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41391-020-00316-x/MediaObjects/41391_2020_316_Fig1_HTML.png)
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
![Overall Survival (OS) for mCRPC patients treated with docetaxel for a... | Download Scientific Diagram Overall Survival (OS) for mCRPC patients treated with docetaxel for a... | Download Scientific Diagram](https://www.researchgate.net/publication/348748378/figure/fig4/AS:990427347943427@1613147689357/Overall-Survival-OS-for-mCRPC-patients-treated-with-docetaxel-for-a-median-3171.png)
Overall Survival (OS) for mCRPC patients treated with docetaxel for a... | Download Scientific Diagram
![Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41391-018-0121-2/MediaObjects/41391_2018_121_Fig1_HTML.png)
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases
![Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors | SpringerLink Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-021-01823-6/MediaObjects/12325_2021_1823_Fig2_HTML.png)
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors | SpringerLink
![Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study | In Vivo Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study | In Vivo](https://iv.iiarjournals.org/content/invivo/35/6/3509/F3.large.jpg)
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study | In Vivo
![The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study - ScienceDirect The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1558767319302757-fx1.jpg)
The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study - ScienceDirect
![Optimal sequencing of commonly used medications for treatment of metastatic castration-resistant prostate cancer - Mayo Clinic Optimal sequencing of commonly used medications for treatment of metastatic castration-resistant prostate cancer - Mayo Clinic](https://www.mayoclinic.org/-/media/kcms/gbs/medical-professionals/images/2020/02/21/15/03/prostate-cancer-survival-graph-767x535px.jpg)
Optimal sequencing of commonly used medications for treatment of metastatic castration-resistant prostate cancer - Mayo Clinic
![Cancers | Free Full-Text | Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer Cancers | Free Full-Text | Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer](https://www.mdpi.com/cancers/cancers-13-00268/article_deploy/html/images/cancers-13-00268-g001.png)